These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22653845)

  • 1. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
    Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
    J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.
    Tselepis C; Perry I; Dawson C; Hardy R; Darnton SJ; McConkey C; Stuart RC; Wright N; Harrison R; Jankowski JA
    Oncogene; 2002 Sep; 21(39):6071-81. PubMed ID: 12203119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time gated fluorescence spectroscopy in Barrett's oesophagus.
    Ortner MA; Ebert B; Hein E; Zumbusch K; Nolte D; Sukowski U; Weber-Eibel J; Fleige B; Dietel M; Stolte M; Oberhuber G; Porschen R; Klump B; Hörtnagl H; Lochs H; Rinneberg H
    Gut; 2003 Jan; 52(1):28-33. PubMed ID: 12477755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence.
    Götzel K; Chemnitzer O; Maurer L; Dietrich A; Eichfeld U; Lyros O; Moulla Y; Niebisch S; Mehdorn M; Jansen-Winkeln B; Vieth M; Hoffmeister A; Gockel I; Thieme R
    BMC Gastroenterol; 2019 Mar; 19(1):38. PubMed ID: 30841855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
    Wang DH; Clemons NJ; Miyashita T; Dupuy AJ; Zhang W; Szczepny A; Corcoran-Schwartz IM; Wilburn DL; Montgomery EA; Wang JS; Jenkins NA; Copeland NA; Harmon JW; Phillips WA; Watkins DN
    Gastroenterology; 2010 May; 138(5):1810-22. PubMed ID: 20138038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
    Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
    Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risk in Barrett's oesophagus.
    Dias Pereira A; Suspiro A; Chaves P
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett's esophagus: a matched case-control study.
    Helminen O; Melkko J; Saarnio J; Sihvo E; Kuopio T; Ohtonen P; Kauppila JH; Karttunen TJ; Huhta H
    Virchows Arch; 2022 Sep; 481(3):467-476. PubMed ID: 35614270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metallothionein in human oesophagus, Barrett's epithelium and adenocarcinoma.
    Coyle P; Mathew G; Game PA; Myers JC; Philcox JC; Rofe AM; Jamieson GG
    Br J Cancer; 2002 Aug; 87(5):533-6. PubMed ID: 12189552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDKN2A-p16 Deletion and Activated KRAS
    Sun J; Sepulveda JL; Komissarova EV; Hills C; Seckar TD; LeFevre NM; Simonyan H; Young C; Su G; Del Portillo A; Wang TC; Sepulveda AR
    Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
    Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
    Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's oesophagus: the new endoscopic modalities have a future.
    Deviere J
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
    Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
    Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.
    Puccio I; Khan S; Butt A; Graham D; Sehgal V; Patel D; Novelli M; Lovat LB; Rodriguez-Justo M; Hamoudi RA
    Int J Exp Pathol; 2018 Feb; 99(1):10-14. PubMed ID: 29473241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
    Griffiths EA; Pritchard SA; McGrath SM; Valentine HR; Price PM; Welch IM; West CM
    Br J Cancer; 2007 May; 96(9):1377-83. PubMed ID: 17437013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
    Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
    Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.